|
Chỉ định và Liều dùng
Oral
Osteoarthritis Adult: Initially, 12.5 mg once daily. Max: 25 mg/day. Oral Pain relief Adult: Initially, 50 mg once daily followed by daily doses of 25-50 mg. Max: 50 mg/day. Treatment duration >5days is not recommended. Oral Rheumatoid arthritis Adult: 25 mg daily. Max: 25 mg/day.
|
|
Suy gan
Max: 12.5 mg/day.
|
|
Chống chỉ định
Hypersensitivity. Severe renal impairment.
|
|
Thận trọng
Hepatic dysfunction, pregnancy and lactation. History of ulcer disease or GI bleeding. Elderly or debilitated patients. Prolonged treatment, smoking and alcoholism may increase risk of GI bleeding. Ischaemic heart disease.
|
|
Tác dụng không mong muốn
Mouth ulcers, chest pain, weight gain, atopic eczema, muscle cramps, diarrhoea, headache, nausea; upper respiratory tract infection, hypertension, ischaemia, dyspepsia, epigastric discomfort, heart burn, nausea, sinusitis, back pain, headache, bronchitis, urinary tract infections.
Potentially Fatal: Renal failure; nephrotoxicity; MI. |
|
PO: C, Z (NSAIDs caused foetal ductus arteriosus premature closure, foetal renal impairment and persistent pulmonary hypertension. Avoid near term, else use lowest dose for shortest time.)
|
|
Quá liều
General supportive measures and clinical monitoring should be used.
|
|
Tương tác
Increases plasma concentrations of methotrexate and lithium. Increased nephrotoxicity when used with thiazide, loop diuretics and ACE inhibitors. May reduce efficacy of loop diuretics.
|
|
Tương tác với thức ăn
High fat meals may delay time to reach peak plasma concentrations.
|
|
Tác dụng
Description:
Mechanism of Action: Rofecoxib selectively inhibits cyclooxygenase-2 (COX-2) enzyme that is involved in the synthesis of prostaglandins. It has no significant inhibitory action on cyclooxygenase-1 (COX-1) enzymes. Onset: 45 min. Duration: >24 hr. Pharmacokinetics: Absorption: Well absorbed from the GI tract (oral); peak plasma concentrations after 2 hr. Distribution: Protein-binding: 85%. Metabolism: Extensively hepatic by reduction to cis- and trans-dihydrorofecoxib. Excretion: Urine and faeces; 17 hr (elimination T1/2 at steady state). |
|
Bảo quản
Store at 25°C.
|
|
Phân loại MIMS
|
Đăng xuất
